BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

An Evaluation of a Customized Insole to Provide Relief From Heel Pain Due to Plantar Fasciitis or General Heel Pain When Used in Footwear Over a Period of Four Weeks

Not Applicable

Completed

Conditions: Foot Orthoses

Interventions: Device: BPI1000013

First Posted Date: 2018-04-25

Last Posted Date: 2019-07-26

Lead Sponsor: Bayer

Target Recruit Count: 102

Registration Number: NCT03507478

Locations: 🇺🇸
Stephens & Associates, Inc., Richardson, Texas, United States
🇺🇸
Thomas J. Stephens & Associates, Inc., Phoenix, Arizona, United States

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Phase 1

Completed

Conditions: Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)
Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma
Advanced Recurrent Serous Ovarian Cancer
Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma

Interventions: Drug: BAY2287411

First Posted Date: 2018-04-25

Last Posted Date: 2023-03-20

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT03507452

Locations: 🇫🇮
HUS, Meilahden sairaala, Helsinki, Finland
🇳🇱
Nederlands Kanker Instituut, Amsterdam, Netherlands
🇳🇱
Universitair Medisch Centrum Groningen, Groningen, Netherlands

and more 4 locations

REALIsM-HF Pilot Study

Not Applicable

Completed

Conditions: Heart Failure

Interventions: Device: AVIVO Mobile Patient Management (MPM) System
Device: VitalPatch biosensor
Device: DynaPort Move Monitor

First Posted Date: 2018-04-25

Last Posted Date: 2023-07-03

Lead Sponsor: Bayer

Target Recruit Count: 27

Registration Number: NCT03507439

Locations: 🇩🇪
Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇩🇪
Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany

and more 2 locations

Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Vericiguat (BAY1021189)
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2018-04-20

Last Posted Date: 2020-04-17

Lead Sponsor: Bayer

Target Recruit Count: 74

Registration Number: NCT03504982

Locations: 🇩🇪
Universitätsherzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Baden-Württemberg, Germany
🇳🇱
Center for Human Drug Research, Leiden, Netherlands
🇩🇪
Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

and more 5 locations

Copanlisib Chinese PK Study

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Copanlisib (Aliqopa, BAY80-6946)

First Posted Date: 2018-04-13

Last Posted Date: 2021-05-19

Lead Sponsor: Bayer

Target Recruit Count: 13

Registration Number: NCT03498430

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis

Phase 1

Completed

Conditions: Psoriasis
Healthy Volunteers

Interventions: Other: Matching Placebo
Drug: BAY1834845
Drug: Midazolam

First Posted Date: 2018-04-10

Last Posted Date: 2021-02-26

Lead Sponsor: Bayer

Target Recruit Count: 72

Registration Number: NCT03493269

Locations: 🇩🇪
PAREXEL GmbH, Berlin, Germany
🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

Non-interventional, Real Life Study on Satisfaction With LNG-IUS in Spanish Young Women (18-30 Years Old) With Different Parity Status and Menstrual Bleeding Pattern

Completed

Conditions: Contraception

Interventions: Drug: Levonogestrel IntraUterine System (LNG-IUS)

First Posted Date: 2018-04-10

Last Posted Date: 2023-11-02

Lead Sponsor: Bayer

Target Recruit Count: 587

Registration Number: NCT03493295

Locations: 🇪🇸
Many locations, Multiple Locations, Spain

Rogaratinib (BAY1163877) Human Mass Balance Study

Phase 1

Completed

Conditions: Clinical Trial, Phase I
Pharmacokinetics

Interventions: Drug: Rogaratinib (BAY1163877)

First Posted Date: 2018-04-02

Last Posted Date: 2018-08-14

Lead Sponsor: Bayer

Target Recruit Count: 6

Registration Number: NCT03484585

Locations: 🇳🇱
PRAHealthSciences, Groningen, Netherlands

Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone

Completed

Conditions: Hypogonadism

Interventions: Drug: Testosterone Product

First Posted Date: 2018-03-30

Last Posted Date: 2019-05-14

Lead Sponsor: Bayer

Target Recruit Count: 27778

Registration Number: NCT03484260

Locations: 🇩🇪
Many Locations, Berlin, Germany

A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia

Phase 1

Completed

Conditions: Hemophilia A; Hemophilia B

Interventions: Drug: BAY1093884

First Posted Date: 2018-03-29

Last Posted Date: 2020-09-16

Lead Sponsor: Bayer

Target Recruit Count: 6

Registration Number: NCT03481946

Locations: 🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy